The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells.

@article{VzquezMartn2009TheAD,
  title={The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells.},
  author={Alejandro V{\'a}zquez-Mart{\'i}n and Cristina Oliveras-Ferraros and Javier A. Men{\'e}ndez},
  journal={Cell cycle},
  year={2009},
  volume={8 1},
  pages={88-96}
}
Population studies have revealed that treatment with the antidiabetic drug metformin significantly associates with reduced breast cancer risk. Animal studies have shown that metformin suppresses the development of mammary carcinomas in transgenic female mice carrying a HER2 oncogene, but not that of spontaneous tumors. We herein demonstrate that HER2 oncoprotein itself may represent a key cellular target involved in the anti-breast cancer actions of metformin. First, ectopical overexpression of… CONTINUE READING
106 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 106 extracted citations

Similar Papers

Loading similar papers…